HB 1194 (see companion bill SB 1023) – MarylandStatus: Inactive / Dead
Year Introduced: 2018
ESTABLISHING THE DRUG COST REVIEW COMMISSION: Providing for the purpose and membership of the Commission to establish an all-payer drug rate setting program. Requires brand and generic manufacturers to report certain information to the commission if launch prices or price increases exceed certain thresholds. The commission, in consultation with stakeholders, would determine if drugs create affordability challenges in the state and if so, the commission would determine a reimbursement rate that would create affordability.